BioPlus Acquisition Corp. (NASDAQ:BIOS – Get Rating) was the target of a large drop in short interest in December. As of December 15th, there was short interest totalling 1,400 shares, a drop of 53.3% from the November 30th total of 3,000 shares. Based on an average daily volume of 41,500 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the shares of the stock are short sold.
Hedge Funds Weigh In On BioPlus Acquisition
A number of large investors have recently made changes to their positions in the stock. Millennium Management LLC increased its holdings in shares of BioPlus Acquisition by 13.6% in the 2nd quarter. Millennium Management LLC now owns 1,124,521 shares of the company's stock valued at $11,178,000 after purchasing an additional 135,001 shares in the last quarter. Polar Asset Management Partners Inc. grew its stake in BioPlus Acquisition by 31.0% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 1,056,666 shares of the company's stock valued at $10,619,000 after acquiring an additional 250,000 shares during the last quarter. Cantor Fitzgerald L. P. grew its stake in BioPlus Acquisition by 6.3% in the 3rd quarter. Cantor Fitzgerald L. P. now owns 850,000 shares of the company's stock valued at $8,542,000 after acquiring an additional 50,000 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in BioPlus Acquisition in the 1st quarter valued at about $8,152,000. Finally, Starboard Value LP acquired a new stake in BioPlus Acquisition in the 1st quarter valued at about $6,098,000. Hedge funds and other institutional investors own 72.81% of the company's stock.
Get
BioPlus Acquisition alerts:
BioPlus Acquisition Stock Performance
Shares of BIOS traded up $0.04 during trading hours on Friday, reaching $10.25. The company had a trading volume of 10 shares, compared to its average volume of 14,359. The firm has a 50 day simple moving average of $10.17 and a 200-day simple moving average of $10.06. BioPlus Acquisition has a 12-month low of $9.78 and a 12-month high of $10.23.
BioPlus Acquisition Company Profile
(Get Rating)
BioPlus Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the life sciences industry. The company was incorporated in 2021 and is based in New York, New York.
Further Reading
- Get a free copy of the StockNews.com research report on BioPlus Acquisition (BIOS)
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
- 3 High-Yield Dividend Stocks to Hold for the Long Haul
Receive News & Ratings for BioPlus Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioPlus Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
